Recent studies have unveiled promising connections between GLP-1 medications and a decreased likelihood of developing certain cancers, coinciding with the increased availability and declining prices of semaglutide in Canadian pharmacies. These findings were presented at the American Society of Clinical Oncology meeting in Chicago, where a multitude of studies suggested that patients using these drugs exhibited lower cancer risks, enhanced survival rates, and improved responses to various treatments compared to those who did not partake in GLP-1 therapy.
Promising Findings from Recent Studies
Dr. Judith Bray, Vice-President of Research at the Canadian Cancer Society, expressed optimism regarding the research outcomes, calling them “transformative.” She highlighted that the scientific community has begun to recognise the potential of GLP-1 medications in cancer prevention, noting, “These rumbling or smoking guns have been firing off for well over a year now about this possibility. So, all of a sudden, the whole research world woke up.”
One notable study published in the ESMO Annals of Oncology examined over 161,000 patients, predominantly aged 47, who were either obese without diabetes or had not been diagnosed with obesity-related cancers. Participants were divided into two groups: one receiving weight-loss injections and the other receiving diet and exercise consultations. Those on GLP-1 medications demonstrated a remarkable 41% reduction in the risk of being diagnosed with obesity-related cancer during the follow-up period.
Investigating Associations with Breast Cancer
Further to these findings, a study released on June 2 in JCO Oncology Practice established a link between GLP-1 treatment and a lower incidence of breast cancer, independent of various factors including age, race, ethnicity, BMI, and diabetes status. This research, conducted between January 1, 2022, and June 30, 2025, identified over 110,000 patients aged 45 to 80 who had undergone breast imaging. Among these, nearly 14% were prescribed GLP-1 medications.
The results indicated that women on GLP-1 drugs had up to a 35% lower risk of developing breast cancer compared to those not using these medications. A more refined analysis matching over 15,000 women using GLP-1s with a control group showed a nearly 31% lower likelihood of breast cancer among those on the treatment. Lead researcher Dr. Elizabeth McDonald acknowledged that while the study is observational and does not definitively establish causation, it adds significant weight to the argument for further exploration of GLP-1 medications as potential cancer prevention agents.
The Urgent Need for Continued Research
Dr. Bray emphasised that more extensive research is crucial to understand whether GLP-1 drugs could also help in reducing the likelihood of cancer recurrence. “If someone already had cancer and then was placed on one of these drugs, would it actually delay or prevent them from developing metastatic disease?” she questioned, acknowledging that the answers remain elusive.
Statistics Canada reported that from 2022 to 2024, 68% of Canadian adults aged 18 to 79 had a body mass index (BMI) classified as overweight or obese, marking a significant increase from 60% prior to the COVID-19 pandemic. This statistic underscores the pressing need to address obesity-related health issues, including cancer.
A Call for Canadian Research
Kimberly Carson, CEO of Breast Cancer Canada, described the new research as “very encouraging” and expressed hope that it could lead to innovative cancer prevention strategies. “It’s very exciting moving forward, and I really love the progress we’re making here,” she remarked. Carson also highlighted the necessity for more Canadian-focused studies in this area, stating, “I’d love to see some Canadian data on this; we’re not looking at any Canadian data yet, and I think we do have the capacity to run a study like this in Canada. There’s an opportunity for Canada.”
Why it Matters
The emerging evidence linking GLP-1 medications to reduced cancer risks may revolutionise our understanding of obesity treatments and their broader implications for cancer prevention. As healthcare professionals advocate for more rigorous research in this field, the potential benefits extend beyond individual health outcomes—potentially influencing public health strategies surrounding obesity and cancer prevention in Canada and beyond. The implications of these findings could lead to innovative treatment protocols and a shift in how we approach the interconnection between obesity and cancer, ultimately saving lives and transforming the healthcare landscape.
